Heparin sodium injection, indications for the treatment of acute deep vein thrombosis. Coagulation in the extracorporeal circulation system during hemodialysis and hemofiltration to prevent acute renal failure or chronic renal insufficiency. Treatment of unstable coronary artery disease, such as unstable angina and non-q-wave myocardial infarction. Prevention of surgically related thrombosis.
Da heparin sodium injection is an anti - blood suppository containing da heparin sodium. Da heparin sodium is a kind of low molecular weight heparin sodium, which comes from the mucous membrane of pig intestine, and its average molecular weight is 5000. Mainly through antithrombin (AT), da heparin can enhance its inhibition of coagulation factor Xa and thrombin, so as to play its antithrombotic role. The ability of this product to enhance the inhibition of coagulation factor Xa is higher than its ability to prolong the plasma coagulation time (APTT). The effect of this product on platelet function and platelet adhesion is less than that of heparin, so it has little effect on primary hemostasis. Some of the antithrombotic properties of this product are thought to be mediated by the vascular wall or fibrinolysis system.
The acute toxicity of da heparin sodium is much lower than that of heparin. The most obvious response repeated in toxicology studies was local bleeding at the injection site after large doses. The incidence and degree of this reaction are dose-related and not cumulative. Local bleeding response was associated with dose-related changes in anticoagulation and was measured by APTT and anti-xa activity. At the same dose, there was no stronger osteopenia than heparin. No organ toxicity was found regardless of the route of administration, dose, or duration of treatment. No mutagenic reaction was found. No fetal toxicity, teratogenic effects and effects on fertility, perinatal period or postpartum were found.